Rapid health technology assessment of the effectiveness,safety and economy of tenofovir disoproxil fumarate in blocking mother-to-child transmission of HBV
TAN Sitao
LIU Xiaoxia
HUANG Hai
ZHANG Li
HE Ying
CHEN Xiaoyu
Abstract：Objective To compare the effectiveness,safety and economy of tenofovir disoproxil fumarate(TDF)and other oral nucleos(t)ide analogues(NAs)in blocking mother-to-child transmission of hepatitis B virus(HBV)by using rapid health technology assessment(HTA)method,and to provide reference for rational administration of medication in clinic.Methods The English databases including PubMed,Embase and the Cochrane Library,and the Chinese databases including China National Knowledge Infrastructure(CNKI),Wanfang Med Online and VIP were systematically searched.At the same time,the official websites and related databases of HTA agencies at home and abroad were searched.The comprehensive HTA reports,systematic review(SR)/Meta-analysis and pharmaceutical economics(PE)studies on the clinical effectiveness and safety of TDF blocking mother-to-child transmission of HBV were summarized and analyzed.Results A total of 15 papers were included,including 11 papers on SR/Meta analysis and 4 papers on PE studies.The results of effectiveness evaluation showed that TDF was superior to lamivudine(LAM)and telbivudine(LDT)in the effectiveness indicators of inhibiting maternal HBV replication and preventing mother-to-child transmission of HBV.The results of safety evaluation showed that there was no significant difference in the incidence of adverse reactions between TDF and LAM as well as between TDF and LDT(P＞0.05).The economic evaluation revealed that TDF had economic advantages in China and South Africa.Conclusion The effectiveness of TDF in blocking mother-to-child transmission of HBV is superior to that of LAM and LDT,and the safety of TDF is comparable to that of the other NAs.TDF has economic advantages in China.
Keywords：Tenofovir disoproxil fumarate(TDF)Hepatitis B virus(HBV)Mother-to-child transmissionNucleos(t)ide analogues(NAs)Health technology assessment(HTA)Pregnant woman
Publication Date：2025-08-30
Online Publishing Date：2025-09-22(First online date of this platform, not the publication date of the document)
Pages：6( 903-908 )